CAAS Capital Management’s Immunocore IMCR Stock Holding History
Bought
Maintained
Sold
Other funds holding IMCR
BBA
RSCM
RI
GA
APM
GF
BCPEMI
PA
CAAS Capital Management's IMCR Position: Q2 2021 in Review
CAAS Capital Management sold out of Immunocore (IMCR) in Q2 2021, closing a stake of 15,000 shares — an estimated $639K sold.
CAAS Capital Management first reported a position in IMCR in Q1 2021 and held it in 1 quarter. The position peaked at $639K in Q1 2021. 45 funds tracked by Wall St. Rank hold IMCR as of Q2 2021.
- CAAS Capital Management reported no remaining Immunocore position as of Q2 2021 after selling out during the quarter.
- CAAS Capital Management sold 15,000 Immunocore shares in Q2 2021, an estimated $639K.
- CAAS Capital Management first reported a position in Immunocore in Q1 2021 and held it in 1 quarter.
- CAAS Capital Management's Immunocore position peaked at $639K in Q1 2021.
- 45 funds tracked by Wall St. Rank held Immunocore as of Q2 2021.
Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.